Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic intracoronary rh-proUK during primary PCI for STEMI
ChiCTR2100047095Phase 4Completed
- Sponsor
- Anqing Municipal Hospital
- Start
- Aug 2021
- Modality
- Small Molecules, Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human prourokinase, tirofiban and saline in myocardial infarction (MI) and acute ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by Anqing Municipal Hospital. Primary endpoint: Corrected TIMI frame count. Started Aug 2021; status: completed.
02
Drugs
recombinant human prourokinasetirofibansaline
03
Conditions
myocardial infarction (MI)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on ChiCTR2100047095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047095.